Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 6.8 weeks
- Canadian FPI
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 6.2 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 7.8 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 9 weeks
BN44715
Parkinson’s Disease Phase III
- 10.4 weeks
- 1st site activated in Canada
BN44715
Parkinson’s Disease Phase III
- 10.6 weeks
BP41072
Lymphome Phase III
- 14.2 weeks
C2321008
Prostate Cancer Phase III
- 11.4 weeks
- 1st site activated in Canada
C2321008
Prostate Cancer Phase III
- 11.6 weeks
C2321008
Prostate Cancer Phase III
- 11.6 weeks
C2321008
Prostate Cancer Phase III
- 10.2 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
- 8.4 weeks
- 1st site activated in Canada
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
- 8.8 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
- 14.8 weeks
C4551002
Breast Cancer Phase III
- 9.4 weeks
- 1st site activated in Canada and Canadian FPI
C4551002
Breast Cancer Phase III
- 20.6 weeks
C4551002
Breast Cancer Phase III
- 16.6 weeks
C4551002
Breast Cancer Phase III
- 19.6 weeks
C4921003
Heart Failure Phase II
- 12.2 weeks
C4921003
Heart Failure Phase II
- 12.4 weeks
C4921003
Heart Failure Phase II
- 14.4 weeks
CA071-1000
Prostate Cancer Phase III
- 8.8 weeks
- 1st site activated in Canada
CA071-1000
Prostate Cancer Phase III
- 10.6 weeks
CA071-1000
Prostate Cancer Phase III
- 12.8 weeks
CA071-1000
Prostate Cancer Phase III
- 10.6 weeks
- Canadian FPI
CA240-0030
Oncology (Metastatic Pancreatic Ductal Adenocarcinoma) Phase II/III
- 10.4 weeks
- 1st site activated in Canada
CA244-0001
Advanced Solid Tumors Phase I/II
- 9.6 weeks
- 1st site activated in Canada and 2nd site activated worldwide
CA244-0001
Advanced Solid Tumors Phase I/II
- 12.4 weeks
- 2nd site activated in Canada and 3rd site activated worldwide
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 8 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 11.6 weeks
CA244-0008 (IZABRIGHT)
Breast Cancer Phase II/III
- 12 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 16.4 weeks
- 1st site activated in Canada
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 17 weeks
CA245-0001
Extensive-Stage Small Cell Lung Cancer Phase III
- 22 weeks